Revvity Stock Gains 5% After Hiking 2025 Profit Outlook

Revvity Boosts 2025 Outlook, Sending Shares Up 5%

Revvity shares climbed 5% in pre-market trading Tuesday after the health-sciences company increased its full-year 2025 financial outlook. The preliminary results, released late Monday ahead of a presentation at the JPMorgan Healthcare Conference, surpassed Wall Street expectations.

Revvity now anticipates fourth-quarter revenue of $772 million, beating the analyst consensus of $757 million. For the full year 2025, the company projects revenue of $2.85 billion and expects earnings per share (EPS) to rise above its prior guidance range of $4.90 to $5.00. This updated forecast stands above the consensus estimate of $4.90 EPS.

Analysts Divided as Stock Approaches $112 Target

Despite the positive guidance, Wall Street analysts are split on the stock's future, with 48% holding a 'Buy' rating and 48% a 'Hold'. The pre-market price of $109 brings the stock close to the average analyst price target of $112.31, consuming much of the previously implied upside. This puts pressure on the company to deliver a strong outlook for the year ahead.

The stock entered Tuesday's session having fallen 9% over the past 12 months. Investors will now focus on the company's official earnings report on February 2, where its guidance for 2026 will be critical in determining whether analysts will turn more bullish and upgrade their ratings.